Phase I Study to Determine the Maximum Tolerable Dose of BAY94-9343 in Patients With Advanced Solid Tumors.

NCT01439152 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

148

Enrollment

INDUSTRY

Sponsor class

Conditions

Oncology

Interventions

DRUG: BAY94-9343
DRUG: BAY94-9343 (Expansion)
DRUG: BAY94-9343 (1.8 mg/kg)
DRUG: BAY94-9343 (2.2 mg/kg)

Sponsor

Bayer